Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.77 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 6/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104875 | 0.93 | METTL3 (0.88) | METTL3GAAEGFRMAPTCFD | |
| SCHEMBL26076709 | 0.93 | METTL3 (0.88) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL19829420 | 0.93 | METTL3 (0.88) | METTL3GAAEGFRMAPTCFD | |
| SCHEMBL11948686 | 0.91 | METTL3 (0.76) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL11948688 | 0.89 | METTL3 (0.75) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL11948687 | 0.88 | METTL3 (0.69) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL13942147 | 0.88 | METTL3 (0.86) | METTL3GAAEGFRMAPTTP53 | |
| SCHEMBL13693054 | 0.88 | METTL3 (0.86) | METTL3GAAEGFRMAPTTP53 | |
| Elvitegravir SCHEMBL726252 | 0.87 | METTL3 (1.00) | METTL3GAAEGFRMAPTTP53 | |
| Elvitegravir SCHEMBL13225651 | 0.87 | METTL3 (1.00) | METTL3GAAEGFRMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420821-B2 | Process for production of 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8383819-B2 | Method for producing 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20090318702-A1 | PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318702-A1 | PROCESS FOR PRODUCTION OF 4-OXOQUINOLINE COMPOUND | CYP4X1, CYP3A4, CYP3A7 | METTL3 1453/4885GAA 1603/4885EGFR 4499/4885 |
| US-20090036684-A1 | METHOD FOR PRODUCING 4-OXOQUINOLINE COMPOUND | IMPDH1, IMPDH2, CDK20 | METTL3 938/4885GAA 2926/4885EGFR 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.